NASDAQ · Biotechnology

Kiora Pharmaceuticals, Inc. (KPRX) Stock

$2.53 +0.00% NASDAQ: KPRX Healthcare

Valuation

MetricValue
Price$2.53
Market Cap$11.21M
P/E Ratio-1.02
P/B Ratio0.94
P/S Ratio0.00
EPS (TTM)$-2.64
52-Week High$2.95
52-Week Low$1.76
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-63.39%
ROA-46.21%
ROCE-59.90%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.02
Current Ratio5.50

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$16.0M$0
Operating Profit$-14.0M$-12.0M$-13.0M$5.0M$-9.0M
Net Profit$-14.0M$-14.0M$-13.0M$4.0M$-11.0M
EPS$-68.00$-18.55$-24.25$0.87$-2.64
Op Margin———28.2%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$20.0M$19.0M$14.0M$36.0M$24.0M
Total Liabilities$6.0M$7.0M$8.0M$11.0M$8.0M
Cash$8.0M$6.0M$2.0M$4.0M$9.0M
Borrowings$0$0$0$0$0

Latest News

SS Innovations International (SSII) Appoints Sarah Romano as Chief Financial Officer NewMediaWire · Jul 15, 2026 SS Innovations names Sarah Romano as CFO MedTech Dive · Jul 15, 2026 Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium TMX Newsfile · Jul 2, 2026 Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model TMX Newsfile · Jun 18, 2026 Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update TMX Newsfile · May 8, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-11.0M$-10.0M$-10.0M$9.0M$-10.0M
Investing Cash Flow$0$0$0$-23.0M$14.0M
Financing Cash Flow$0$3.0M$-1.0M$0$0
Net Cash Flow$7.0M$-2.0M$-4.0M$1.0M$5.0M
Free Cash Flow$-11.0M$-10.0M$-10.0M$9.0M$-10.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.05
EV / EBITDA-0.38
FCF Yield-75.92%
Quick Ratio8.97
Interest Coverage0.00
Return 1Y-17.33%
Return 3Y-56.61%
Return 5Y-99.79%

Ownership

Insiders Held3.08%
Institutions Held28.92%
Institutions Float Held29.83%
Institutional HolderSharesReport Date
Adar1 Capital Management, LLC 167,9412026-03-31
Citadel Advisors Llc49,5332026-03-31
Geode Capital Management, LLC47,8502026-03-31
Vanguard Capital Management LLC19,8612026-03-31
Xtx Topco Ltd14,7192026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACXPAcurx Pharmaceuticals, Inc. $1.27 +1.60% -0.36 $5.46M 0.00%
ADILAdial Pharmaceuticals, Inc $4.00 +0.76% -0.26 $10.50M 0.00%
APREAprea Therapeutics, Inc. $0.58 +4.73% -0.64 $7.24M 0.00%
APVOAptevo Therapeutics Inc. $1.81 +0.56% -0.01 $3.96M 0.00%
BCDABioCardia, Inc. $1.07 +0.94% -1.54 $15.93M 0.00%

About Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc. is led by CEO Brian Strem, employs 12 people, headquartered in US, publicly traded since 2015.

Kiora Pharmaceuticals, Inc. (KPRX) stock trades at $2.53 with a market capitalization of $11.21M. The stock is valued at a price-to-earnings (P/E) ratio of -1.02, price-to-book of 0.94, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.76 and $2.95, and currently trades 14.2% below its 52-week high.

On profitability, Kiora Pharmaceuticals, Inc. generates a return on equity (ROE) of -63.39%, return on capital employed of -59.90%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1178.88 +0.79% JNJ Johnson & Johnson $260.45 +1.55% ABBV AbbVie Inc. $276.98 +1.67% MRK Merck & Company, Inc. Common Stock (new) $145.34 +2.08% UNH UnitedHealth Group Incorporated Common Stock (DE) $376.24 +1.43% NVS Novartis AG $143.67 +0.39% AZN AstraZeneca PLC $159.80 +0.64% TMO Thermo Fisher Scientific Inc $658.31 +0.97% AMGN Amgen Inc. $413.31 +1.44% GILD Gilead Sciences, Inc. $150.80 +2.52% ABT Abbott Laboratories $99.69 +1.21% NVO Novo Nordisk A/S $38.39 +0.54%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides